Atherosclerosis is initiated by functional changes in the endothelium accompanied by accumulation, oxidation, and glycation of LDL-cholesterol in the inner layer of the arterial wall and continues with the expression of adhesion molecules and release of chemoattractants. PCSK9 is a proprotein convertase that increases circulating LDL levels by directing hepatic LDL receptors into lysosomes for degradation. The effects of PCSK9 on hepatic LDL receptors and contribution to atherosclerosis via the induction of hyperlipidemia are well defined. Monoclonal PCSK9 antibodies that block the effects of PCSK9 on LDL receptors demonstrated beneficial results in cardiovascular outcome trials. In recent years, extrahepatic functions of PCSK9, particularly its direct effects on atherosclerotic plaques have received increasing attention. Experimental trials have revealed that PCSK9 plays a significant role in every step of atherosclerotic plaque formation. It contributes to foam cell formation by increasing the uptake of LDL by macrophages via scavenger receptors and inhibiting cholesterol efflux from macrophages. It induces the expression of inflammatory cytokines, adhesion molecules, and chemoattractants, thereby increasing monocyte recruitment, inflammatory cell adhesion, and inflammation at the atherosclerotic vascular wall. Moreover, low shear stress is associated with increased PCSK9 expression. PCSK9 may induce endothelial cell apoptosis and autophagy and stimulate the differentiation of smooth muscle cells from the contractile phenotype to synthetic phenotype. Increasing evidence indicates that PCSK9 is a molecular target in the development of novel approaches toward the prevention and treatment of atherosclerosis. This review focuses on the molecular roles of PCSK9 in atherosclerotic plaque formation.

**Key words:** PCSK9, Atherosclerosis, Foam cell, Inflammation, Vascular wall

Atherosclerosis is a chronic condition that starts early in life and then continues lifelong. Atherosclerotic process begins with functional changes in the endothelium accompanied by accumulation, oxidation, and glycation of low-density lipoprotein (LDL) cholesterol in the inner layer of the arterial wall and continues with the expression of adhesion molecules and the release of chemoattractants. Monocytes and T cells are recruited in the intimal space, where monocytes engulf the oxidized LDL and become foam cells. Fatty streaks, the earliest lesions of atherosclerosis, can be visualized in the aorta from the first decade of life. They appear in the coronary arteries in the second decade and in the cerebral arteries from the third or fourth decades. Fatty streaks develop into atherosclerotic plaques, which can lead to luminal narrowing of the arteries causing ischemic complaints or plaque may become unstable, leading to acute atherothrombotic events.

Among the various risk factors of atherosclerosis, dyslipidemia—particularly LDL cholesterol—plays the main role in the initiation and progression of the atherosclerotic process. As confirmed by several experimental and clinical studies, there is a clear, log-linear relationship between the LDL cholesterol level and atherosclerosis. Circulating LDL cholesterol level is mainly determined by the number of hepatic LDL cholesterol receptors (LDLR) and the expression or the activity of proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme.

Proprotein convertases are a family of proteins that are responsible for post-translational modifica-
tions of many functional proteins, including proteolytic cleavage, and activation of most polypeptide hormones such as proinsulin. Hepatic PCSK9 is the circulating protein that regulates the half-life of LDL in the liver. In the absence of PCSK9, LDLR binds to LDL on the hepatocyte surface, transfers it into endosomes inside the hepatocyte, and recycles back to the cell surface to bind and internalize new LDL particles. Binding with PCSK9 routes the LDLR to lysosomal degradation, and the recycling of the LDLR is blocked. Endocytosis of PCSK9-mediated LDLRs occurs both via clathrin- and caveolae-dependent pathways, whereas recycling of LDLR and PCSK9 complex occurs in clathrin-dependent pathway and degradation occurs in caveolae-dependent pathway. LDLR and PCSK9 complex interaction with adenyl cyclase associated protein-1 (CAP1) leads to caveolae-dependent endocytosis.

PCSK9, synthesized as a 74 kDa zymogen with 692 amino acids, comprises four domains, namely, the N-terminal pro-domain, signal peptide, the catalytic domain, and a C-terminal domain. Autocatalysis occurs between its pro-domain and catalytic domain, and a C-terminal domain. Autocatalysis occurs between its pro-domain and catalytic domain in endoplasmic reticulum. After autocatalysis, the pro-domain remains non-covalently attached to its catalytic pocket, which is unique to this enzyme. N-terminal of pro-domain inhibits convertase activity of PCSK9, preventing it from interacting with surrounding substrates. Therefore, the pro-domain acts to modulate the effect of PCSK9 by releasing the catalytic domain. A short segment of amino acids in the catalytic domain of PCSK9 (amino acids 367 to 380) interacts with the epidermal growth factor-like A domain of LDLR to divert it to endosomes and lysosomes for degradation. The catalytic domain activity of PCSK9 is not required for its effect on LDLR. PCSK9 also escorts very low-density lipoprotein receptor (VLDLR), apolipoprotein E receptor 2 (ApoER2), and LDLR-related protein-1 (LRP1) to lysosomal degradation.

**PCSK9’s Role in Atherosclerotic Process**

The atherogenic effects of PCSK9 were initially explained through its role in lipid metabolism; however, plasma PCSK9 level is only modestly correlated with the plasma lipid levels. In recent years, it has been recognized that beyond its effects on lipid metabolism, PCSK9 also has direct atherothrombotic effects on the vascular wall. Several preclinical and clinical studies showed that the relation of PCSK9 with atherosclerosis can be partly independent of its hyperlipidemic effects. In Apo E knock-out mice, PCSK9 accelerated atherosclerosis without affecting plasma lipid levels, whereas PCSK9 overexpression did not cause an increase in plasma lipids but in atherosclerotic lesion size. The Atheroma IVUS study revealed that the necrotic core volume of the atherosclerotic plaque increases proportionately to serum PCSK9 level independent of LDL cholesterol. A 10 year follow-up study showed that the carotid plaque area and the formation of new carotid plaques are related to LDL levels and also independent to increased PCSK9 levels. Moreover, STAINLAS study cohort revealed that increased PCSK9 level is found to be related to carotid plaque formation. These trials, showing the relation of PCSK9 with atherosclerosis, have drawn attention to direct effects of PCSK9 on atherosclerotic plaques.

Vascular smooth muscle cells (SMCs) are the main PCSK9 secreting cells in the vascular wall. Despite conflicting reports, many studies have shown that endothelial cells also express PCSK9, albeit less than SMCs. Macrophages and human atherosclerotic plaques are other sources of PCSK9 expression. The expression of PCSK9 in various components of the arterial wall contributes to its direct effects in the initiation and progression of the atherosclerotic process. This review summarizes current data on the role of PCSK9 in atherosclerotic plaque formation.

**Effects of PCSK9 in Oxidized LDL Uptake and Cholesterol Efflux**

Atherosclerosis begins with the formation of foam cells, which are macrophages that engulf oxidized LDL (ox-LDL) (Fig. 1). Ox-LDL enters into the monocytes/macrophages and also SMCs and fibroblasts by scavenger receptors (SRs), including class A SR, class B SR type I, CD36, macrosialin (CD68), and lectin-like ox-LDL (LOX-1). LOX-1 is the major receptor in the engulfment of ox-LDL by macrophages and also increases the production of cell surface adhesion molecules and is involved in the process of oxidative stress. PCSK9 induces expression of all SRs, but mostly, LOX-1 on monocytes and SMCs. In inflammatory milieu, PCSK9 and LOX1 induce each other, leading to an increased ox-LDL uptake.

Excess intracellular free cholesterol is toxic for macrophages from which they protect themselves by cholesterol efflux to extracellular acceptors. Inhibiting cholesterol efflux in macrophages causes an increase in foam cell formation. ATP Binding Cassette A1 (ABCA1), ATP Binding Cassette G1 (ABCG1), and Scavenger Receptor Class B Type I (SR-BI) are membrane transporters that provide most cholesterol efflux in macrophages. PCSK9 inhibits ABCA-1-de-
Apolipoprotein (Apo E) is a lipid transport protein and major ligand for LDLR. Parenchymal cells, differentiated macrophages, astrocytic glial cells, and SMCs synthesize and secrete Apo E, which take a role in the transport of cholesterol and other lipids between peripheral tissue and liver, mediating the clearance of chylomicrons and LDL in the liver. Apo E can reduce lipid accumulation in macrophages and inhibit foam cell formation and switching of macrophages from proinflammatory M1 phenotype to anti-inflammatory M2 phenotype. Effects of Apo E are exerted via apoE-receptor-2 (apoER2), which is expressed in platelets, endothelial cells, monocytes, and macrophages. The binding of apoE to apoER2 has protective effect from atherosclerosis by suppressing the inflammatory function of macrophages, reducing lipid accumulation and cell death. ApoER2 is a member of the LDLR family, whose structure is similar to that of LDLR with 46% identity. PCSK9 decreases apoER2 levels with a similar mechanism used for LDLR, namely without using its catalytic activity, by its coexpression or cell surface internalization.

Thereby, PCSK9 inhibits the atheroprotective effects of apoER2 resulting in increased inflammation and foam cell formation.

**PCSK9 in Vascular Inflammation**

PCSK9 induces inflammation in atherosclerosis independently from its hyperlipidemic effect. Disturbed ox-LDL uptake/cholesterol efflux balance and accumulation of ox-LDL stimulates the overlying endothelial cells to produce proinflammatory molecule. In addition to ox-LDL accumulation, PCSK9 can directly induce the expression of inflammatory cytokines. Ly6C(hi) monocytes, also called “inflammatory monocytes”, are associated with acute inflammation. They accumulate in inflammatory sites, promoting monocyte recruitment and local inflammation. In the early atherosclerotic plaques, Ly6C(hi) monocytes infiltrate atherosclerotic lesions and produce activated macrophages, responsible for the secretion of proinflammatory cytokines. In Apo
The nuclear factor kappa B (NF-KB) controls the transcription of many genes that have roles in inflammation and atherosclerosis, including cytokines, chemokines, adhesion molecules, acute phase proteins, regulators of apoptosis, and cell proliferation. NF-KB, mitogen-activated protein kinase, and damaged mitochondrial DNA have significant roles in PCSK9-mediated ox-LDL uptake. NF-KB nuclear translocation is induced by PCSK9 overexpression in macrophages, increasing the mRNA levels of proinflammatory cytokines and toll-like receptor 4 (TLR4) expression. Inversely, NF-KB inhibition decreases LPS, ox-LDL, and TNF-α induced PCSK9 expression. Therefore, it is worth noting that NF-KB has an important signaling role in inflammatory stimulus mediated by PCSK9 expression and PCSK9 accelerates atherosclerotic plaque inflammation through the

![Diagram](image_url)

**Fig. 2. Inflammation**

PCSK9 induces the expression of endothelial adhesion molecules. NF-KB nuclear translocation is induced by PCSK9, leading to an increase in mRNA levels and secretion of inflammatory cytokines.
concentration-dependently (Fig. 3)⁴⁶. In ox-LDL treated HUVECs, expressions of proapoptotic protein Bax and the activity of caspase9 and caspase3 increase, whereas anti-apoptotic protein Bcl-2 expression decreases⁴⁶. The silencing of PCSK9, with its siRNA, reverses the apoptotic effects of ox-LDL and inhibits apoptosis in endothelial cells⁴⁶). Therefore, it is suggested that PCSK9 increases apoptosis of HUVECs by Bcl/Bax - caspase9 - caspase3 pathway⁴¹, ⁴⁶. PCSK9 inhibition also decreases the phosphorylation of c-Jun N-terminal kinase and p38, which play an important role in cell apoptosis that is induced by oxidative damage, IL1, TNF-α, and G protein-coupled receptors⁴¹).

Autophagy is a protective cellular process of self-digestion of the misfolded proteins and dysfunctional organelles. It aims to promote cell survival under unfavorable conditions such as inflammation and oxidative stress. In the early stages of atherosclerosis, autophagy is protective against macrophage engulfment and local inflammation. However, in late stages, it leads to macrophage death, accelerated inflammation, and thinning of fibrous cap by collagen degradation and can cause acute coronary events⁴⁷). The mammalian target of rapamycin (mTOR) is an inhibitor of autophagy, whereas mTOR inhibitor rapamycin is the most commonly used introducer of autophagy, providing a possible anti-atherosclerotic effect⁴¹). PCSK9 upregulation induces mTOR expression in vascular SMC cultures dose-dependently, whereas inhibition of PCSK9 with its siRNA promotes

**Fig. 3. Apoptosis**

PCSK9 induces apoptosis of HUVECs by inducing Bax and inhibiting Bcl2.
ROS production increases PCSK9 levels\(^{23}\). Mitochondrial ROS induce apoptosis of endothelial and vascular SMCs. Elevated ROS production provokes endothelial dysfunction, induces the infiltration and activation of inflammatory cells, and increases the expression of proinflammatory adhesion molecules; therefore, differentiation to synthetic SMC contributes to the formation of foam cells\(^{56}\). PCSK9, which can be induced by resistin, insulin, and hemodynamic shear stress in SMCs, induces SMC differentiation to synthetic phenotype and increases migration and proliferation of synthetic type SMCs\(^{23, 57, 58}\).

**Shear Stress-Induced PCSK9 Expression**

Vascular tone and diameter are under the control of vascular SMCs through the mechanism of contraction\(^{51}\). Vascular SMCs are highly specialized cells of which principal functions are contraction and regulation of blood vessel tone, blood pressure, and blood flow. Local susceptibility to atherosclerosis is regulated by blood flow patterns. Endothelial shear stress is one of the mechanical factors that initiate atherosclerotic plaques. It is the tangential stress derived from the friction of the flowing blood on the endothelial surface of the arterial wall. Low shear stress, which typically occurs in regions of branching or bifurcation regions of the arteries, results in high EC turnover, increased accumulation of LDL, increased oxidative stress, increased DNA synthesis, and higher expression of proinflammatory adhesion molecules; therefore, low shear stress is related to atherosclerosis\(^{52}\). It has been shown that low shear stress (3–6 dyne/cm\(^2\)) increases PCSK9 expression mostly in the SMCs, and lipid-induced increase in PCSK9 expression is higher at low shear stress\(^{23}\).

**PCSK9’s Effects on Vascular SMCs**

Vascular SMCs within adult blood vessels exhibit a low rate of proliferation and low synthetic activity and express contractile proteins. SMCs in the media express contraction proteins such as alpha-smooth muscle actin, myosin heavy chain II, and calponin, whereas intimal SMCs synthesize extracellular matrix, proteases, and cytokines and have higher migratory and proliferative capacity\(^{53, 54}\). Contractile SMCs can differentiate to a synthetic phenotype with atherogenic stimuli such as shear stress, cytokines, and ROS\(^{55}\). Synthetic SMCs proliferate and migrate more rapidly, synthesize more collagen, increase lipid synthesis, and express higher levels of SRs; therefore, differentiation to synthetic SMC contributes to the formation of foam cells\(^{56}\). PCSK9, which can be induced by resistin, insulin, and hemodynamic shear stress in SMCs, induces SMC differentiation to synthetic phenotype and increases migration and proliferation of synthetic type SMCs\(^{23, 57, 58}\).

PCSK9 deficiency protects arteries partially from neointimal formation\(^{59}\). There is an increased number of the synthetic phenotype of SMCs and increased PCSK9 expression in acute aortic dissection samples\(^{60}\). In aortic dissection with medial aortic calcification (MAC), PCSK9 expression is higher than in aortic dissection without MAC\(^{60}\). Thus, it can be suggested that PCSK9 plays a role in aortic dissection by contributing to the loss of structural integrity of aorta\(^{60}\).

**Micro-RNAs Targeting PCSK9 Expression**

Micro-RNAs (miRNAs) are short non-coding RNAs (18–22 nucleotides) that function in RNA silencing and controlling post-transcriptional regulation of gene expression\(^{61}\). They initiate the degradation or inhibit the translation of their target mRNA by binding to the recognition element on the 3’-UTR\(^{62}\). By affecting gene expression, they participate in the regulation of gene expression. Being specific for a given cell and tissue, they influence the phenotype of the cell in which they are expressed. They can be found free in the circulation, bound to proteins or high density lipoprotein (HDL), and in exosomes. By entering body fluids such as blood or urine, they relay signals from the producer cell to distant targets. Their expression has been correlated with various diseases, including coronary artery disease, and they have been reported to be involved in all phases of atherosclerosis, particularly immune cell recruitment and cytokine release.
Many miRNAs may affect PCSK9 expression. MiR-17-5p, a potential biomarker for the diagnosis of coronary atherosclerosis, inhibits VLDLR expression in vascular SMCs via direct binding to its 3′-UTR. Inhibition of miR-17-5p induces upregulation of VLDLR and downregulation of PCSK9 in atherosclerotic apoE −/− mice, miR-191, miR-222, and miR-224 can bind the 3′ end of the PCSK9 mRNA and thus regulate PCSK9 expression. When cells are transfected with vectors overexpressing miR-191, miR-222, and miR-224, significant downregulation of PCSK9 is observed.

Hypomethylation and elevated expression of miR-191 promote epithelial to mesenchymal transition in hepatocellular carcinoma. EGR1 (early growth response protein 1) is a zinc finger transcription factor that has a binding site on the PCSK9 promoter. miR-191 targets EGR1 and can regulate PCSK9 expression in different physiological states.

In a study by Vickers et al., miR-222 level in circulating HDL was found to be 8.2-fold higher in familial hypercholesterolemia patients compared with HDL from normal subjects. miR-222 regulates insulin sensitivity, and miR-222 levels are higher in plasma of obese human patients. It is an important regulator in lipid metabolic pathways and a negative regulator of adipocyte differentiation. It has been reported that miR-222 plays important roles in many physiological and pathological processes in the cardiovascular system; it also plays a role in atherosclerosis and plaque formation. Moreover, miR-222 has been reported to decrease the PCSK9 expression.

miR-27a induces an increase in PCSK9 and consequently decreases LDLR levels by 40% via enhancing LDLR degradation. Silencing PCSK9 repressed miR-27a and, to a lesser extent, let-7c.

Further studies are required to delineate the role of miRNAs in PCSK9 regulation.

**Conclusion**

After its discovery in 2003, knowledge on PCSK9 has gone from bench-to-bedside in less than 9 years, and PCSK9 monoclonal antibodies entered into dyslipidemia guidelines since 2016. Although the role of PCSK9 in LDL metabolism is well defined, recent studies have revealed that it has various effects on many metabolic pathways, including inflammation, sepsis, sodium metabolism, glucose metabolism, and atherosclerosis. Signals of these metabolic pathways also affect PCSK9’s level and function.

It is now clear that PCSK9 contributes to every step of the molecular pathway of atherosclerosis. Despite the rapidly accumulating data on its atherogenic effects, much is still unknown, including its signaling pathways and receptors in atherosclerosis, its acting mechanisms on vascular cells in atherosclerosis, its role in vascular diseases such as aneurysms, its interaction and signal transduction through receptors other than LDLR, the extent of miRNA regulation of PCSK9, and its relevance. Furthermore, it should not be overlooked that, although PCSK9 is a member of the proprotein convertase family, its substrate for convertase activity and why it exists are still unknown. To clarify its role in atherosclerosis and its reason for existence, further research is required.

**Acknowledgements**

The authors gratefully acknowledge use of the services and facilities of the Koç University Research Center for Translational Medicine (KUTTAM), funded by the Presidency of Turkey, Presidency of Strategy and Budget. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Presidency of Strategy and Budget.

**Conflicts of Interest**

None.

**References**

1) Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, Tokgözoğlu L and Lewis EF: Atherosclerosis. Nat Rev Dis Primers, 2019; 5: 56
2) Chistiakov DA, Melnichenko AA, Myasoedova VA, Grechko AV and Orekhov AN: Mechanisms of foam cell formation in atherosclerosis. J Mol Med (Berl), 2017; 95: 1153-1165
3) Luis A: Atherosclerosis. Nature, 2000; 407: 233-241
4) Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J and Lisheng L: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, 2004; 364: 937-952
5) Fernández-Friera L, Fuster V, Lópezmelgar B, Oliva B, García-Ruiz JM, Mendiguren J, Bueno H, Pocsok S, Ibáñez B, Fernández-Ortiz A and Sanz J: Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors. J Am Coll Cardiol, 2017; 70: 2979-2991
6) Nordrægaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, RaaL FJ, Desfesce JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Borén J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E,
Taskinen MR and Tybjærg-Hansen A: Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J, 2013; 34: 3478-3490a

7) Schulz R and Schlüter KD: PCSK9 targets important for lipid metabolism. Clin Res Cardiol Suppl, 2017; 12: 2-11

8) Seidah NG, Abifadel M, Prost S, Boileau C and Prat A: The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9. Pharmacol Rev, 2017; 69: 33-52

9) Shapiro MD, Tavori H and Fazio S: PCSK9: From Basic Science Discoveries to Clinical Trials. Circ Res, 2018; 122: 1430-1438

10) Jang HD, Lee SE, Yang J, Lee HC, Shin D, Lee H, Lee J, Jin S, Kim S, Lee SJ, You J, Park HW, Nam KY, Lee SH, Park SW, Kim JS, Kim SY, Kwon YW, Kwak SH, Yang HM and Kim HS: Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9. Eur Heart J, 2020; 41: 239-252

11) Naureckiene S, Ma L, Sreekumar K, Purandare U, Lo CF, Ma L, Sreekumar K, Purandare U, Lo CF: Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms. Cardiovasc Res, 2016; 110: 268-278

12) Seidah NG, Abifadel M, Prost S, Boileau C and Prat A: The proprotein convertase neural apoptosis-regulating enzyme (NARC)-1: liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A, 2003; 100: 928-933

13) Seidah NG, Abifadel M, Prost S, Boileau C and Prat A: The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov, 2012; 11: 367-383

14) Kume N, Murase T, Moriwaki H, Aoyama T, Sawamura T, Masaki T and Kita T: Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res, 2007; 100: 1634-1642

15) Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, Cheng JM, Oemrawsingh RM, Garcia-Garcia HM: OX-LDL uptake in macrophages. Cardiovasc Res, 2018; 114: 1145-1153

16) Mehta JL, Sanada N, Hu CP, Chen J, Dandapat A, Sugawara F, Satoh H, Inoue K, Kawase Y, Jishage K, Suzuki H, Takeya M, Schnackenberg L, Beger R, Hermonat PL, Thomas M and Sawamura T: Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res, 2007; 100: 1634-1642

17) Kume N, Murase T, Moriwaki H, Aoyama T, Sawamura T, Masaki T and Kita T: Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res, 1998; 83: 322-327

18) Ding Z, Liu S, Wang X, Fan Y, Sun C, Wang Y and Mehta JL: Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta. Antioxid Redox Signal, 2015; 22: 760-771

19) Ding Z, Liu S, Wang X, Theus S, Deng X, Fan Y, Zhou S and Mehta JL: PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages. Cardiovasc Res, 2018; 114: 1145-1153

20) Mehta JL, Sanada N, Hu CP, Chen J, Dandapat A, Sugawara F, Satoh H, Inoue K, Kawase Y, Jishage K, Suzuki H, Takeya M, Schnackenberg L, Beger R, Hermonat PL, Thomas M and Sawamura T: Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res, 2007; 100: 1634-1642

21) Kume N, Murase T, Moriwaki H, Aoyama T, Sawamura T, Masaki T and Kita T: Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res, 2007; 100: 1634-1642

22) Mehta JL, Sanada N, Hu CP, Chen J, Dandapat A, Sugawara F, Satoh H, Inoue K, Kawase Y, Jishage K, Suzuki H, Takeya M, Schnackenberg L, Beger R, Hermonat PL, Thomas M and Sawamura T: Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res, 2007; 100: 1634-1642
32) Mahley RW: Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. J Mol Med (Berl), 2016; 94: 739-746

33) Bai XQ, Peng J, Wang MM, Xiao J, Xiang Q, Ren Z, Wen HY, Jiang ZS, Tang ZH and Liu LS: PCSK9: A potential regulator of apoE/apoER2 against inflammation in atherosclerosis? Clin Chim Acta, 2018; 483: 192-196

34) Leeb C, Eresheim C and Nimpf J: Clusterin is a ligand for apolipoprotein E receptor 2 (ApoER2) and very low density lipoprotein receptor (VLDLR) and signals via the Reelin-signaling pathway. J Biol Chem, 2014; 289: 4161-4172

35) Wältmann MD, Basford JE, Konaniah ES, Weintraub NL and Hui DY: Apolipoprotein E receptor-2 deficiency enhances macrophage susceptibility to lipid accumulation and cell death to augment atherosclerotic plaque progression and necrosis. Biochim Biophys Acta, 2014; 1842: 1395-1405

36) Reddy SS, Connor TE, Weaber EJ and Rebeck W: Similarities and differences in structure, expression, and functions of VLDLR and ApoER2. Mol Neurodegener, 2011; 6: 30

37) Ruscica M, Tokgózoğlu L, Corsini A and Sirtori CR: PCSK9 inhibition and inflammation: A narrative review. Atherosclerosis, 2019; 288: 146-155

38) Leiva E, Wehinger S, Guzmán L and Orrego R: Role of Oxidized LDL in Atherosclerosis. In: Hypercholesterolemia, 2015: 1-6

39) Swirski FK, Libby P, Aikawa E, Alcalde P, Luscinskas FW, Weissleder R and Pittet MJ: Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheroma. J Clin Invest, 2007; 117: 195-205

40) Giunzioni I, Tavori H, Covarrubias R, Major AS, Ding L, Zhang Y, DeVay RM, Hong L, Fan D, Predazzi IM, Rashid S, Linton MF and Fazio S: Local effects of human PCSK9 on the atherosclerotic lesion. J Pathol, 2016; 238: 52-62

41) Li J, Liang X, Wang Y, Xu Z and Li G: Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis. Mol Med Rep, 2017; 16: 1817-1825

42) Ricci C, Ruscica M, Camera M, Rossetti L, Macchi C, Colciago A, Zanotti I, Lupo MG, Adorni MP, Cicero AFG, Fogacci F, Corsini A and Ferri N: PCSK9 induces a pro-inflammatory response in macrophages. Sci Rep, 2018; 8: 2267

43) Tang ZH, Peng J, Ren Z, Yang J, Li TT, Li TH, Wang Z, Wei DH, Liu LS, Zheng XL and Jiang ZS: New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway. Atherosclerosis, 2017; 262: 113-122

44) De Winther MPJ, Kanters E, Kraal G, Hofker MH: Nuclear factor κB signaling in atherogenesis. Arterioscler Thromb Vasc Biol, 2005; 25(5): 904-914

45) Liu A and Frostegård J: PCSK9 plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque. J Intern Med, 2018; 284: 193-210

46) Wu CY, Tang ZH, Jiang L, Li XF, Jiang ZS and Liu LS: PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bel/Bax-caspase9-caspase3 pathway. Mol Cell Biochem, 2012; 359: 347-358

47) Sun Y and Guan X-r: Autophagy: A new target for the treatment of atherosclerosis. Frontiers in Laboratory Medicine, 2018; 2: 68-71

48) Cai Z, He Y and Chen Y: Role of Mammalian Target of Rapamycin in Atherosclerosis. Curr Mol Med, 2018; 18: 216-232

49) Ding Z, Liu S, Wang X, Mathur P, Dai Y, Theus S, Deng X, Fan Y and Mehta JL: Cross-Talk Between PCSK9 and Damaged mtDNA in Vascular Smooth Muscle Cells: Role in Apoptosis. Antioxid Redox Signal, 2016; 25: 997-1008

50) Cammisotto V, Pastorì D, Nocella C, Bartimoccia S, Castellani V, Marchese C, Scavalli AS, Ettorre E, Viceconte N, Violì F, Pignatelli P and Carnevale R: PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation. Antioxidants (Basel), 2020; 9: 296

51) Chistiakov DA, Orekhov AN and Bobryshev YV: Vascular smooth muscle cell in atherosclerosis. Acta Physiol (Oxf), 2015; 214: 33-50

52) Chatzizisis YS, Coskun AU, Jonas M, Edelman ER, Feldman CL and Stone PH: Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol, 2007; 49: 2379-2393

53) Campbell JH and Campbell GR: The role of smooth muscle cells in atherosclerosis. Curr Opin Lipidol, 1994; 5: 323-330

54) Worth NF, Rolfe BE, Song J and Campbell GR: Vascular smooth muscle cell phenotypic modulation in culture is associated with reorganisation of contractile and cytoskeletal proteins. Cell Motil Cytoskeleton, 2001; 49: 130-145

55) Orr AW, Hastings NE, Blackman BR and Warnhoff BR: Complex regulation and function of the inflammatory smooth muscle cell phenotype in atherosclerosis. J Vasc Res, 2010; 47: 168-180

56) Campbell JH, Popadyynec L, Nestel PJ and Campbell GR: Lipid accumulation in arterial smooth muscle cells. Influence of phenotype. Atherosclerosis, 1983; 47: 279-295

57) Melone M, Wilise L, Palyha O, Strack A and Rashid S: Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9. J Am Coll Cardiol, 2012; 59: 1697-1705

58) Costet P, Cariou B, Lambert G, Lalanne F, Lardeux B, Jarnoux AL, Greffhorst A, Staels B and Kramp M: Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem, 2006; 281: 6211-6218

59) Faghih N, Marchiano S, Tibolla G, Baetta R, Dhyani A, Heys S, Ruscica M, Ubaldi P, Catapano AL and Cosentino A: PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. Atherosclerosis, 2016; 253: 214-224

60) Iida Y, Tanaka H, Sano H, Suzuki Y, Shimizu H and Urano T: Ectopic Expression of PCSK9 by Smooth Muscle Cells Contributes to Aortic Dissection. Ann Vasc Surg, 2018; 48: 195-203

61) Liu N and Olson EN: MicroRNA regulatory networks in
cardiovascular development. Dev Cell, 2010; 18: 510-525
62) Filipowicz W, Bhattacharya SN and Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet, 2008; 9: 102-114
63) Navickas R, Gal D, Laučevičius A, Taparauskaitė A, Zdanytė M and Holvoet P: Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review. Cardiovasc Res, 2016; 111: 322-337
64) Martens CR, Bansal SS and Accornero F: Cardiovascular inflammation: RNA takes the lead. J Mol Cell Cardiol, 2019; 129: 247-256
65) Mottazi AA, Banach M, Pirro M, Stein EA and Sahebkar A: MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia? Clin Rev Allergy Immunol, 2018; 54: 224-233
66) Tănă L, Meng L, Shi X and Yu B: Knockdown of microRNA-17-5p ameliorates atherosclerotic lesions in ApoE(-/-) mice and restores the expression of very low density lipoprotein receptor. Biotechnol Lett, 2017; 39: 967-976
67) Næli P, Mirzadeh Azad F, Malakootian M, Seidah NG and Mowlà SJ: Post-transcriptional Regulation of PCSK9 by miR-191, miR-222, and miR-224. Front Genet, 2017; 8: 189
68) He Y, Cui Y, Wang W, Gu J, Guo S, Ma K and Luo X: Hypomethylation of the hsa-miR-191 locus causes high expression of hsa-mir-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma. Neoplasia, 2011; 13: 841-853
69) Di Leva G, Piovan C, Gasparini P, Ngankeu A, Taccioli C, Briskin D, Cheung DG, Bolon B, Anderlucci L, Alder H, Nuovo G, Li M, Iorio MV, Galasso M, Santhanam R, Marcucci G, Perrotti D, Powell KA, Bratasz A, Garofalo M, Nephew KP and Croce CM: Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor sta-

10

tus. PLoS Genet, 2013; 9: e1003311
70) Ortega FJ, Mercader JM, Catalán V, Moreno-Navarrete JM, Pueyo N, Sabater M, Gómez-Ambrosi J, Anglada R, Fernández-Formoso JA, Ricart W, Frühbeck G and Fernández-Real JM: Targeting the circulating microRNA signature of obesity. Clin Chem, 2013; 59: 781-792
71) Price NL and Fernández-Hernando C: miRNA regulation of white and brown adipose tissue differentiation and function. Biochim Biophys Acta, 2016; 1861: 2104-2110
72) Bazan HA, Hatfield SA, O’Malley CB, Brooks AJ, Lightell D, Jr. and Woods TC: Acute Loss of miR-221 and miR-222 in the Atherosclerotic Plaque Shoulder Accompanies Plaque Rupture. Stroke, 2015; 46: 3285-3287
73) Alvarez ML, Khosroheidari M, Eddy E and Done SC: MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis. Atherosclerosis, 2015; 242: 595-604
74) Walley KR, Thain KR, Russell JA, Reilly MP, Meyer NJ, Ferguson JF, Christie JD, Nakada TA, Fjell CD, Thair SA, Cirstea MS and Boyd JH: PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci Transl Med, 2014; 6: 258ra143
75) Sharoti V, Collier DM, Olson DR, Zhou R and Snyder PM: Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9). J Biol Chem, 2012; 287: 19266-19274
76) Mbikay M, Sirois F, Mayne J, Wang GS, Chen A, Dewpura T, Prat A, Seidah NG, Chretien M and Scott FW: PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett, 2010; 584: 701-706
77) Spolitu S, Okamoto H, Dai W, Zadroga JA, Wittchen ES, Gromada J and Ozcan L: Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol. Circ Res, 2019; 124: 38-51